Previous 10 | Next 10 |
Zynex ( NASDAQ: ZYXI ) shares gained 3% Tuesday morning after the medical technology company announced an additional $10M share buyback authorization. The program will commence on Nov. 1, 2022 and is scheduled to terminate on Oct. 31, 2023 or when the $10.0 million buy...
At the heart of the medical device space isn’t just new technologies for diagnostics but also substitutes for potentially addictive and life-destroying drugs. Anything you can do with physical-external stimuli instead of pills that impact the brain is possibly a life-changing option fo...
Zynex, Inc. (ZYXI) Q3 2022 Earnings Conference Call October 27, 2022 4:15 AM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Dan Moorhead – Chief Fin...
Zynex press release ( NASDAQ: ZYXI ): Q3 GAAP EPS of $0.13. Revenue of $41.52M (+19.3% Y/Y). Q4 2022 Guidance: The estimated range for fourth quarter 2022 revenue is between $48-$51 million, an increase of approximately 23% from Q4 2021. Adjusted EBITDA for the fou...
Zynex Announces 2022 Third Quarter Earnings PR Newswire ENGLEWOOD, Colo. , Oct. 27, 2022 /PRNewswire/ -- Zynex, Inc . (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...
Zynex, Inc. to Announce Third Quarter 2022 Financial Results PR Newswire ENGLEWOOD, Colo. , Oct. 13, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive me...
Zynex ( NASDAQ: ZYXI ) on Tuesday reported record order growth in Q3 and reiterated its guidance. Q3 orders increased 34% Y/Y and 12% sequentially. "Aug. and Sept. saw the highest number of monthly orders in ZYXI's history. Additionally, cash collections ...
Zynex Reports Preliminary Third Quarter 2022 Results PR Newswire ENGLEWOOD, Colo. , Oct. 11, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical de...
The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently sitting on their highest cash allocation levels ever. According Sentimentrader.com, large investors are currently sitting on their largest ...
Summary Zynex has succumbed to extensive short selling in 2021-22 that may be in the process of reconsidering bearish bets. Projected growth rates for the company are exceptionally positive, on new product releases. Valuations are extremely low if analyst estimates prove corre...
News, Short Squeeze, Breakout and More Instantly...
Zynex Sets Second Quarter 2024 Earnings Call PR Newswire ENGLEWOOD, Colo. , July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain manage...
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces PR Newswire ENGLEWOOD, Colo. , July 11, 2024 /PRNewswire/ -- Zy...